<DOC>
	<DOCNO>NCT00537979</DOCNO>
	<brief_summary>Prospective , non-randomized , multi-center study ass efficacy safety paricalcitol injection oral administer 6 month patient secondary hyperparathyroidism dialysis .</brief_summary>
	<brief_title>Efficacy Safety 6 Months Treatment With Paricalcitol Injection Oral Patients With Secondary Hyperparathyroidism Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Patients &gt; =18 year secondary hyperparathyroidism ( iPTH &gt; = 300 pg/mL ) Patients chronic hemodialysis peritoneal dialysis program previously treat vitamin D metabolite without previous treatment Patients treatment paricalcitol injection oral clinically indicate accord criterion participate investigator Patients provide sign informed consent participate trial Patients severe hyperparathyroidism ( iPTH &gt; 3,000 pg/ml ) Patients hypercalcaemia ( calcium &gt; =11.0 mg/dl , adjust accord Albumin level ) , hyperphosphataemia ( phosphorus &gt; = 6.5 mg/dl ) patient calcium x phosphorus &gt; = 70 Known hypersensitivity and/or toxicity vitamin D metabolites and/or product ingredient Patients participate clinical study within last month currently enrol clinical study Patients tolerate take phosphorus binder contain Calcium and/or Aluminum Patients opinion investigator , reason , good candidate therapy Synthetic Analogues Vitamin D</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Zemplar</keyword>
</DOC>